FDA Issues Warning Letter to Medical Spa for DSCSA Violations

The U.S. FDA has issued a warning letter to Pure Indulgence Aesthetics, a medical spa, for significant violations of the Drug Supply Chain Security Act (DSCSA). The inspection, conducted on December 2, 3, and 12, 2025, revealed that the facility sourced botulinum neurotoxin type A products from unauthorized trading partners. The FDA found discrepancies between the spa's purchase records and patient treatment records, suggesting the administration of drugs obtained from non-compliant sources. Additionally, an unlabeled vial containing drug ingredients was discovered, lacking required product identifiers. This marks the first enforcement action against a dispenser under the DSCSA, indicating a shift in regulatory focus. The spa's response to the FDA's concerns was deemed inadequate. The violations pose risks of counterfeit and harmful drugs being administered to patients. The FDA's action emphasizes the need for compliance among all entities dispensing prescription drugs.

Key Points: • FDA issued a warning letter to a medical spa for DSCSA violations. • The spa sourced drugs from unauthorized trading partners, risking patient safety. • This is the first enforcement action against a dispenser under the DSCSA.